alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 10,026–10,050 of 10,985 studies · free to read (page 402 of 440) · 27,380 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Improving Early Detection of Dementia: Extra Trees-Based Classification Model Using Inter-Relation-Based Features and K-Means Synthetic Minority Oversampling Technique

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Big Data and Cognitive Computing 2025-05-30

The early detection of dementia, a condition affecting both individuals and society, is essential for its effective management. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Systemic disadvantages facing UK ethnic elders within dementia healthcare

✓ Peer-reviewed alzhub usefulness score 35 out of 100. BJPsych Advances 2025-07-02

Reduced access to dementia healthcare services by elders from ethnic minority backgrounds is often a manifestation of underlying systemic disadvantages within dementia assessment and treatment services. 5 key findings →

Design: narrative review Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Do Older Mexican Americans With Dementia Benefit From Living Closer to the Border? Evidence From the HEPESE

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Hispanic Journal of Behavioral Sciences 2025-01-10

Hispanic older adults face significant barriers to healthcare access, stemming from multiple factors: limited income, high medical costs, elevated rates of chronic disease and dementia, and greater reliance on public insurance programs, relative to other racial, ethnic, and age groups. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Effects of Medicare predictors in health disparities in the risk of Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Alzheimer s & Dementia Translational Research & Clinical Interventions 2025-04-01

Low income and vulnerability to arterial hypertension were the primary contributors to AD/ADRD disparities, with cerebrovascular diseases and depression as notable secondary predictors. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Leveraging Artificial Intelligence in the Diagnosis of Neurodegenerative Disorders (Alzheimer's and Dementia) and in Managing Medication Schedules"

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Damanhour Journal of Intelligent Systems and Informatics 2025-06-01

The Alzheimer's disease (AD) is recognized as one of the most common neurodegenerative causes of dementia worldwide, having been characterized by progressive cognitive decline for the most part. 2 key findings →

Participants: 461 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

‘Machine Learning’ multiclassification for stage diagnosis of Alzheimer’s disease utilizing augmented blood gene expression and feature fusion

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Discover Applied Sciences 2025-06-12

Three blood gene expression datasets of high dimensionality and low sample size (HDLSS) have been utilized in this study, with one dataset exhibiting significant class imbalance. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Loneliness during the COVID-19 pandemic: A potential risk factor for post-pandemic cognitive decline in older adults without dementia

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Dementia & Neuropsychologia 2025-01-01

A total of eight studies were included from 1,384 search results, reviewing data from 10,449 cognitively unimpaired older adults. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Mitochondrial Reactive Oxygen Species Production in Vascular Dementia Following Experimental Diabetes

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Cells 2025-08-15

Type 1 diabetes (T1D) is a serious disease which affects millions of people worldwide and is a major factor for vascular contributions to cognitive impairment and dementia (VCID). 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Functional connectivity differences in the default mode and frontoparietal networks in older adults with Down syndrome are related to obstructive sleep apnea

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Alzheimer s & Dementia 2025-12-01

We observed higher within‐ and between‐DMN FC in the CS‐OSA compared to the CI‐OSA group; however, this difference was not observed between the CS‐nonOSA and CI‐nonOSA groups. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Hippocampal mitophagy alterations in MAPT-associated frontotemporal dementia with parkinsonism

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Acta Neuropathologica Communications 2025-02-24

The enzyme pair PINK1 and PRKN together orchestrates a cytoprotective mitophagy pathway that selectively tags damaged mitochondria with phospho-serine 65 ubiquitin (pS65-Ub) and directs them for autophagic-lysosomal degradation (mitophagy). 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Graph Spectral Analysis Using Electroencephalography in Alzheimer Disease and Frontotemporal Dementia Patients

✓ Peer-reviewed alzhub usefulness score 35 out of 100. International Journal of Neural Systems 2025-06-12

Graph theory has proven to be useful in studying brain dysfunction in Alzheimer’s disease using MagnetoEncephaloGraphy (MEG) and fMRI signals. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Neuroprotective, Antioxidant and Anti-Inflammatory Effect of Greek Pomegranate Seed Oil on N2a Neuroblastoma Cells and Mild Cognitive Impairment Patients

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Biology 2025-05-15

Alzheimer’s disease (AD) remains a significant global health challenge with limited FDA-approved treatments, necessitating the search for novel preventive strategies. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Unraveling the conformational landscape of amyloid precursor protein intracellular domain

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Biophysical Journal 2025-08-15

The amyloid precursor protein intracellular domain (AICD), a cleavage product of amyloid precursor protein implicated in Alzheimer disease and amyloid lateral sclerosis, is a functionally important but structurally elusive intrinsically disordered protein. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

γ-Secretase exosites as targets for substrate-selective lowering of Aβ generation

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Structure 2025-12-19

Intramembrane proteolysis by γ-secretase is critically implicated in Alzheimer disease pathogenesis by processing of its amyloid precursor protein substrate C99 into harmful amyloid-β peptide (Aβ) species. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

From clinical judgment to biology: a clinician's opinion on the use of blood-based biomarkers in Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Frontiers in Neurology 2026-04-08

This position is justified by the fact that not all individuals with positive biomarkers will progress to symptomatic disease, as well as by the considerable variability in biomarker results depending on the type of marker and the laboratory performing the analysis (3).Both frameworks agree that biomarkers enhance diagnostic certainty but differ in the degree of reliance placed upon them. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed